PROSPECTIVE-STUDY OF FLUCONAZOLE THERAPY IN SYSTEMIC NEONATAL FUNGAL INFECTION

Background. Standard neonatal systemic antifungal therapy with amphote ricin B and flucytosine can be associated with toxicity, drug resistan ce and the need for prolonged venous access. There is consequently a n eed for alternative treatment options. Objectives. To assess the effic acy and safety of fluconazole in the treatment of systemic neonatal fu ngal infections. Method. Open, nonrandomized evaluation of fluconazole treatment in 20 consecutively enrolled neonates with systemic fungal infection. Results. Clinical and microbiologic cure was achieved in 12 of 19 (63%) of infants treated. One additional infant received prior amphotericin B therapy and is included for assessment of side effects. One infant with Torulopsis glabrata infection failed treatment. Six i nfants died of Gram-negative bacterial infection and other intercurren t medical problems. Conclusion. Fluconazole appeared to be safe and ef fective for treatment of systemic candidal infection in the neonate al though more data are required in very low birth weight infants.